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The difficulty of accessing the mitochondrial matrix
has limited the targeting of therapeutics to this organ-
elle. Here, we report, to our knowledge, the first
successful delivery of an active DNA alkylating
agent—chlorambucil—tomitochondria, anddescribe
unexpected features that result from rerouting this
drug within the cell. Mitochondrial targeting of this
agent dramatically potentiates its activity, and
promotes apoptotic cell death in a variety of cancer
cell lines and patient samples. This retention of
activity is observed even in cells with resistance to
chlorambucil or disabled apoptotic triggering.
INTRODUCTION
The energy-producing capacity of mitochondria (mt) is contin-
gent on the preservation of a barrier limiting the permeation of
ions or other small molecules. The highly hydrophobic, densely
packed structure of the inner mitochondrial membrane is impen-
etrable to most molecular species—a property critical for the
proton gradient that directs oxidative phosphorylation (Muratov-
ska, et al., 2001). However, the impermeability of this inner
membrane impedes the delivery of drug molecules that could
impact the other important biological role of mt—apoptotic trig-
gering (Taylor, et al., 2008). Given that apoptotic resistance is
observed in many types of cancer cells (Hanahan andWeinberg,
2000), being able to intervene by targeting apoptotic agents to
mt could enable the development of new anticancer strategies.
In an effort to provide carriers for mitochondrial delivery of bioac-
tive cargo, our group recently developed mitochondria-pene-
trating peptides (MPPs) that can efficiently traverse both the
plasma membrane and mitochondrial membranes with a variety
of attached cargos (Horton, et al., 2008; Yousif, et al., 2009).
Here, we investigate the impact of mitochondrial delivery of
a cargo with clinically relevant anticancer activity, the nitrogen
mustard chlorambucil (Cbl). Cbl is a potent alkylating agent
that is used to treat leukemia, and its activity is linked to alkyl-
ation of the nuclear genome (Begleiter, et al., 1996). We report
the rerouting of this agent to the mt and document the uniqueChemistry & Biology 18,ability of this organelle-specific drug, mt-Cbl, to evade two
commonly observed resistance mechanisms that deactivate
cancer therapeutics.
RESULTS AND DISCUSSION
Generation of a Mt-Targeted Form of Cbl and Initial
Toxicity Testing
Cbl was selected as an ideal drug for mitochondrial delivery
because it exhibits rapid reaction kinetics and does not require
cellular activation. In addition, the carboxylic acid moiety
provides an ideal functional group for facile attachment to an
MPP. To generate mt-Cbl, the drug was coupled to an
MPP with the sequence FxrFxrFxr (Fx = cyclohexylalanine, r =
d-arginine) (Figure 1A). The peptide sequence was designed
based on previous work indicating that the inclusion of cyclohex-
ylalanine units within a sequence introduces sufficient hydropho-
bicity to allow penetration of the mitochondrial membranes,
whereas cationic units drive uptake across the energized barrier
enclosingmt (Horton, et al., 2008). Penetration of the peptide into
the mitochondrial matrix was confirmed with a biotinylated MPP
that could be visualized by immunogold TEM (Figure 1B; see Fig-
ure S1A available online). This peptide is comprised entirely of
artificial amino acids, which make it resistant to intracellular
degradation. The peptide was generated by conventional
solid-phase synthesis, and the drug was then attached by
coupling to a C-terminal lysine residue. Retention of the alkyl-
ation activity (Figure S1B) and DNA-crosslinking activity (Fig-
ure S1C) of Cbl in the mitochondrially targeted conjugate were
confirmed in vitro.
Initial confirmation ofmitochondrial localization for mt-Cbl was
obtained by generating a labeled conjugate with the fluorophore
thiazole orange (Carreon, et al., 2007) coupled to the N terminus
of the peptide. In live HeLa cells, mt-Cbl localization strongly
correlated with that of themt-specific dyeMitoTracker, suggest-
ing that Cbl successfully accumulated within the mt (Figure 1C).
The cytotoxicity of mt-Cbl toward HeLa cells was compared to
the parent peptide and unconjugated Cbl. Using a cell viability
assay, a 100-fold increase in potency was observed with mt-Cbl
compared to Cbl (Figure 1D). The parent peptide did not show
appreciable toxicity in the concentration range tested, indicating
that cell death resulted from the activity of the drug and not the
vector.445–453, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 445
Cbl 
MPP 
to A 
mt-Cbl mitotracker overlay 
C 
100 nm 
B
-7 -6 -5 -4
0
25
50
75
100
log [Fxr3kCbl] (M)
mt-Cbl 
LC
50
 = 
 3 µM 
Cbl 
LC
50
 > 100 µM 
%
 
T
o
x
i
c
i
t
y
 
log [mt-Cbl] (M) 
MPP 
LC
50
 > 
 100 µM 
0
500
1000
1500
U
n
t
r
e
a
t
e
d
 
4
0
M
 
3
0
0
M
 
1
0
0
M
 
3
M
 
6
M
 
1
2
M
 
M
i
t
o
S
O
X
 
s
i
g
n
a
l
 
mt-Cbl 
0.00
0.05
0.10
0.15
U
n
t
r
e
a
t
e
d
 
4
0
M
 
3
0
0
M
 
1
0
0
M
 
3
M
 
6
M
 
1
2
M
 
J
C
-
1
 
R
a
t
i
o
 
Cbl mt-Cbl Cbl 
p=0.024 
E F D 
N
H
H
N N
H
H
N N
H
H
N N
H
O
O
HN
HN NH2
O
O
HN
HN NH2
O
O
HN
HN NH2
O O NH2
N
NS
N
H
O
N
Cl
Cl
3
0
0
m
Figure 1. Mitochondrial Localization and Toxicity of mt-Cbl
(A) Structure of fluorescently labeled mt-Cbl conjugate used in studies of mitochondrial drug localization. In all other assays an acetyl group replaced the thiazole
orange (to) fluorophore on the peptide N terminus. See also Table S1.
(B) Localization of MPP in mitochondrial matrix as observed by immunogold staining and TEM imaging of isolated mt (see Figure S1A for quantitation and
controls).
(C) Intracellular localization of to-mt-Cbl (green) in live HeLa cells compared with MitoTracker 633 (red).
(D) Toxicity of mt-Cbl toward HeLa cells after 24 hr of incubation. See also Figure S1.
(E) Increased levels of superoxide with mitochondrial targeting of Cbl in HeLa cells. MitoSOX staining and assessment by flow cytometry was consistent with
increasedsuperoxide inmt-Cbl treated samples. (F)Mitochondrial delivery ofCbl depolarizes themitochondrialmembrane inHeLacells.Mitochondrialmembrane
potential was analyzed by flowcytometry of JC-1 staining.Mean values plotted, n = 3, error bars equal SEM. Student’s two-tailed t test used to determine p values.
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Mitochondrial Delivery of ChlorambucilCbl is a clinically used therapeutic indicated for the treatment
of leukemia (Begleiter, et al., 1996). To evaluate the activity and
specificity of mt-Cbl in leukemia cells, we assessed its toxicity
in a panel of leukemia cell lines. Similar levels of toxicity were
observed. For example, in HL60 cells, mt-Cbl again exhibited
an increase in potency compared to Cbl (Table 1), with an
EC50 of 34 and 6.8 mM for Cbl and mt-Cbl, respectively.
Confirmation of the Mitochondrially Directed Activity
of mt-Cbl and Evaluation of the Site of Intracellular
Damage
To confirm that cell death arose from reactions occurring in the
mt, we looked at two mitochondrial properties: membrane
potential and reactive oxygen species (ROS) levels. Mitochon-
drial DNA lesions have been shown to increase ROS and depo-
larize this organelle’s membrane (Santos, et al., 2003). Both446 Chemistry & Biology 18, 445–453, April 22, 2011 ª2011 Elsevierincreased superoxide and decreased membrane potential
were observed upon mt-Cbl treatment (Figures 1E and 1F).
However, Cbl—an agent with activity linked to alkylation of the
nuclear genome—did not produce the same phenotypes at
statistically significant levels. These data support the hypothesis
that mt-Cbl is specifically acting upon mitochondrial targets.
We qualitatively assessed the target of mt-Cbl alkylation within
the cell by incubating HeLa cells with the conjugate, allowing
alkylation to occur and then fixing the DNA within cells and per-
meabilizing their membranes. The mt-Cbl conjugate maintained
its mitochondrial localization, even upon membrane permeabili-
zation, whereas the MPP control peptide diffused from the mt to
the cytoplasm and nucleus upon membrane disruption (Fig-
ure S2A). Following fixation and permeabilization, cells were
further treated with DNase to fragment the DNA, and this re-
sulted in diffusion of mt-Cbl. These observations qualitativelyLtd All rights reserved
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Figure 2. Cbl and mt-Cbl Induce DNA Damage in Different
Organelles
Relative amplification of 17.7 kb nuclear and 8.9 kb mitochondrial DNA
segments. HL60 cells were treated with Cbl (150 mM) or mt-Cbl (3 mM) for 2 hr
prior to PCR analysis. Lesions/10 kb values are included above the graph bars.
See also Figure S2.
Table 1. Summary of EC50 Values in Leukemia Cell Line Panel
Cell Line Cbl EC50 mt-Cbl EC50
OCI-M2 311 ± 24 mM 7.5 ± 1 mM
K562 306 ± 26 mM 8.7 ± 0.4 mM
OCI-LY17 55 ± 7 mM 8.3 ± 1 mM
HL60 34 ± 6 mM 6.8 ± 0.6 mM
U937 34 ± 5 mM 5.9 ± 0.7 mM
OCI-AML2 28 ± 3 mM 6.4 ± 0.4 mM
DAUDI 27 ± 7 mM 9.8 ± 0.8 mM
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Mitochondrial Delivery of Chlorambucilsuggest that mt-Cbl reacts with DNAwithinmt, and it is this inter-
action that accounts for retention of mt-Cbl in membrane-per-
meabilized mt, in contrast to the MPP alone, which lacks the
DNA anchor. In addition, isolation of mtDNA after treatment
using a biotinylated mt-Cbl indicated that mt-Cbl adducts were
present (Figure S2B). This further suggests a covalent attach-
ment of the mt-Cbl to mtDNA.
The alkylation of nuclear versus mitochondrial DNA was quan-
titatively assessed by comparing the efficiency of PCR amplifica-
tion of the two genomes. HL60 cells were treated with either Cbl
or mt-Cbl, and damage of the nuclear and mitochondrial
genomes was assessed independently. A 17.7 kb segment of
nuclear DNA at the b-globin gene and an 8.9 kb fragment ofmito-
chondrial DNA were analyzed. Cbl primarily damaged nuclear
DNA with very few mitochondrial lesions, whereas mt-Cbl
caused a significant reduction of mitochondrial DNA amplifica-
tion with minimal effect on the nuclear genome (Figure 2). These
data suggest that using mt-Cbl specifically targets Cbl’s action
to mitochondrial DNA.
Interestingly, the levels of damage introduced by Cbl and
mt-Cbl in the genomes they target are very similar. Cbl produced
0.42 ± 0.03 lesions per 10 kb in the nuclear genome, and mt-Cbl
produced1.4 ± 0.1 lesions per 10 kb. The similarity in the damage
levels observed, despite Cbl treatment at four times its EC50 and
mt-Cbl treatment at one half its EC50, indicates that mtDNA is
more susceptible to alkylation damage.
Differential Cellular Responses to Targeted
DNA-Damaging Agents
Having two forms of the same drug targeted to two different
organelles provided a unique opportunity to probe how site-
specific events within the cell can lead to different responses.
Wesought to investigate thedownstreameffectsofmitochondrial
DNA alkylation relative to those of nuclear DNA alkylation, and to
identify the pathways involved in detection of mt-DNA damage
and induction of apoptosis. A quantitative real-time PCR array
was employed to assess a panel of 84 genes, ten of which have
mitochondrial activity (Table S2). These ten genes are known to
be involved in DNA damage sensing, repair, apoptosis, and cell-
cycle arrest. Genes were considered to be differentially ex-
pressed if they showed aR4-fold change compared to untreated
cells (Figure S3A), and hits were confirmed with three biological
replicates using individually synthesized PCR primers.
This analysis revealed that different pathways are activated
when nuclear versus mitochondrial DNA alkylation occurs.
DDIT3/GADD153 exhibited a 5-fold increase in expression inChemistry & Biology 18,response to Cbl but no change with mt-Cbl, suggesting that
this gene is primarily involved in responding to nuclear DNA
damage. Two other genes were upregulated to a greater extent
with mt-Cbl relative to Cbl alone: PPP1R15A/GADD34 (4-fold)
and GADD45G (15-fold) (Figure 3). p21 was overexpressed in
the presence of both mt-Cbl and Cbl. These changes in mRNA
levelswereconfirmed to lead toacorrespondingchange inprotein
expression (Figure S3B). Interestingly, none of the genes
mentioned above that are known to be mitochondrially targeted
were affected.
The Growth Arrest and DNA Damage-inducible (GADD) family
of genes are known to be involved in apoptosis and cell-cycle
arrest (Smith and Fornace, 1996), and the p21 protein is also
known to play an important role in DNA damage sensing. p21
has been shown to interact with GADD45G (Fan, et al., 1999),
which can activate p38 or JNK pathways (Lu, et al., 2001). The
activation of these pathways was assessed with immunoblotting
following treatment with Cbl or mt-Cbl, and interestingly, differ-
ential activation was observed, with Cbl activating p38 and
mt-Cbl activating JNK (Figure S3C). These results show that
different cellular responses are mounted when the same
compound is targeted to distinct intracellular sites.
The levels of Ligase III were also investigated in Cbl andmt-Cbl
treated cells. This ligase, present in both the nucleus and mt, is
the only ligase in the latter organelle and is involved in the repair
of most forms of DNA damage (Lakshmipathy and Campbell,
1999). Therefore, in response to mt-Cbl induced damage of the
mitochondrial genome, an increase in expression of this gene
should be observed. Indeed, this was detected in cells treated
with mt-Cbl (Figure 3; Figure S3B).
Activity of mt-Cbl against Primary Human Cells
Having confirmed that we had rerouted Cbl to a new organelle,
the mt, and that we observed an increase in potency with445–453, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 447
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Figure 3. Differing Gene Expression Profiles in Response to DNA Damage by Cbl and mt-Cbl
A qPCR array for genes involved in detecting DNA damage and inducing apoptosis was used to assess RNA expression profiles of HL60 cells treated with LC25
doses of Cbl or mt-Cbl for 2 or 24 hr. To assess Ligase III expression, cells were treated with LC50 doses of Cbl or mt-Cbl for 1 hr. *MPP change in expression
subtracted from mt-Cbl result. Mean values plotted, n = 3, error bars equal SEM. See also Figure S3 and Table S2.
Chemistry & Biology
Mitochondrial Delivery of Chlorambucilcultured cell lines, we then tested the activity of the drug against
primary cancer cells. To determine whether mt-Cbl would show
enhanced activity over the parent compound, we assessed
toxicity profiles for B cells isolated from patients with chronic
lymphocytic leukemia (CLL). To also evaluate the effect of
mt-Cbl on normal cells and to examine whether the compound
has a clinically useful differential toxicity in normal and malignant
cells (i.e., a therapeutic window), the activity of mt-Cbl toward
peripheral blood stem cells (PBSCs) and mononuclear cells
from normal healthy donors was compared to CLL cells from
the peripheral blood of patients. The concentration of mt-Cbl
needed to kill cells of patients with CLL was significantly lower
than for either population of normal cells, indicating that a thera-
peutic window exists for the peptide conjugate (Figure 4A).
Toxicity of mt-Cbl in primary cells of patients with leukemia
was also confirmed through an independent colony-forming
assay (Figure S4A). Furthermore, mt-Cbl showed nominal red
blood cell-hemolysis levels at the concentrations used in this
study (Figure 4A), suggesting a lack of toxicity to these cells at
concentrations where leukemic cells were ablated.
To investigate the source of the therapeutic window, we evalu-
ated the cellular uptake of the MPP in the CLL cells, mononuclear
cells, and PBSCs. MPP uptake in CLL cells was higher than in
normal cells, indicating that higher drug concentrations would
be achieved in these cells (Figure 4B). Moreover, a higher relative
mitochondrialmembranepotentialwasobserved inCLLcells (Fig-
ure 4B), suggesting that there would be a greater driving force for448 Chemistry & Biology 18, 445–453, April 22, 2011 ª2011 Elseviermitochondrial accumulation of mt-Cbl in this type of cell. Further-
more, perturbing mitochondrial membrane potential in HL60 cells
using the proton ionophore FCCP resulted in a decreased uptake
of the MPP, suggesting that mitochondrial membrane potential
has an impact on peptide accumulation (Figure S4B). This differ-
ence in mitochondrial membrane potential between cancer and
normal cells has been widely reported (Davis, et al., 1985), and
differential drug toxicity due to this characteristic has also been
previously observed, such as in studies with the delocalized
lipophilic cations (DLCs) Rhodamine 123 and MKT-077 (Modica-
Napolitano and Aprille, 1987, 2001; Modica-Napolitano, et al.,
1996). However, here, a drug is being delivered that is not
a DLC; and thus, the peptide carrier is providing the necessary
specificity. Therefore, MPPs present a general vector for mito-
chondrial drug delivery with a beneficial therapeutic window.
Activity of mt-Cbl in Drug-Resistant Cells
When the activity of the unmodified drug in a panel ofmyeloid and
lymphoid cell lines (Table 1) was tested, we observed that Cbl
had attenuated potency in two cell lines (K562 and OCI-M2).
These cells were 10-fold more resistant than the rest of the
cohort (Figure 5B and Table 1).Many cancer cell types are known
to increase thresholds for apoptotic induction by altering levels of
proapoptotic or antiapoptotic factors, leading to chemothera-
peutic resistance. To determine whether the Cbl-resistant cells
were generally resistant to apoptosis, we tested the sensitivity
of these lines to staurosporine, an Akt inhibitor and inducer ofLtd All rights reserved
AB
Figure 4. Evaluation of mt-Cbl Activity and Therapeutic Window in primary CLL cells
(A) Cbl and mt-Cbl activity at LC25 and LC50 in red blood cells (healthy donors), PBSCs (healthy donors), mononuclear cells (healthy donors), and cells of patients
with CLL. Both Cbl and mt-Cbl were more selectively toxic to cells of patients with CLL compared to those derived from healthy donors. Percent viability was
determined by FACS analysis of Annexin V/SYTOX Red cell staining. Hemolytic activity of RBCs with Cbl and mt-Cbl was found to be minimal at the concen-
trations used in this experiment. Mean values plotted, n > 5, error bars are SEM. Student’s two-tailed t test used to determine p values.
(B) MPP uptake and mitochondrial membrane potential for peripheral blood cells, mononuclear cells, and cells of patients with CLL. Uptake of thiazole orange
(to)-MPP measured by flow cytometry showed higher levels of peptide uptake in CLL cells. Mitochondrial membrane potential as measured by FACS analysis of
JC-1 staining—with a decreasing JC-1 ratio indicative of lowermitochondrial membrane potential—indicated a highermitochondrial membrane potential for cells
of patients with CLL in comparison to PBSCs and mononuclear cells from healthy donors. Mean values plotted, n = 3, error bars equal SEM.
See also Figure S4.
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Mitochondrial Delivery of Chlorambucilapoptosis. Interestingly, the two Cbl-resistant cell lines showed
reduced rates of apoptotic induction (Figure 5C).
Because overexpression of antiapoptotic factors is a common
mechanism of apoptotic resistance (Lowe and Lin, 2000; Reed,
1998), we investigated the expression level of the antiapoptotic
protein BclXL. BclXL has been shown previously to be overex-
pressed in certain cancers, and its antiapoptotic activity is thought
tocontribute todrug resistance (Minn,etal., 1995). Indeed, in these
two Cbl-resistant lines, we observed a much higher level of BclXL
than in thesensitive lines (Figure5C). Thissuggests thatBclXLover-
expression, and the resulting suppression of apoptosis, may
underlie the resistance to Cbl. In contrast to Cbl, when the activity
of mt-Cbl was tested in this panel using a cell viability assay,
comparable toxicity was observed in all lines tested (Figure 5A).
Testing toxicity in a secondary assay (induction of apoptosis,
Figures 5A and 5B inset), at the EC50 concentrations determined
from the cell viability assay, showed comparable levels of toxicity
(approximately 35% toxicity). In addition the mechanism of cell
death for Cbl and mt-Cbl appeared similar, with early apoptotic
cells apparent by flow cytometry (inset, Figures 5A and 5B). The
fact that the mt-Cbl conjugate still exhibits high levels of cytotox-
icity in these apoptosis-resistant cell lines indicates that the
deliveryofa toxicdrug tomt representsaneffectivemeans toover-
come mechanisms commonly employed by cancer cells to resist
the action of cytotoxic drugs. Mitochondrially localized BclXL is
a component of a pathway that commonly detects apoptotic
stimuli fromsitesoutside themt.TargetingCbl into themt to induce
toxicity within this organelle might allow the cell to overcome or
bypass BclXL overexpression and initiate the apoptotic pathway.
Anothermajor formofdrug resistance incancercells results from
theoverexpressionofenzymesorother factors that facilitatechem-Chemistry & Biology 18,ical deactivation of pharmacophores. For Cbl, inactivation via
glutathione modification is a common mechanism of resistance.
Addition of the glutathione tripeptide to Cbl, a reaction catalyzed
by glutathione S-transferase (GST), not only results in the inactiva-
tion of Cbl (Yang, et al., 1992), but it also promotes efflux from the
cell by pumps that recognize glutathione-modified xenobiotics
(Barnouin, et al., 1998). In order to analyze whether mt-Cbl would
be able to evade drug resistance arising from this type of chemical
inactivation, we tested the activity of this conjugate in a Cbl-resis-
tant ovarian cancer cell line known to overexpress the cytoplasmic
GST-m isoform (Horton, et al., 1999). Using the Annexin-V
apoptosis assay, we observed that Cbl was able to induce cell
death in the wild-type cell line, but in the Cbl-resistant line, toxicity
was insignificant, even at 100 mM (Figure 5D). Interestingly, mt-Cbl
was able to inducecell death at amuch lower concentration (9mM);
this value was comparable in both the wild-type and resistant line.
This finding was also confirmed through an independent cell
viability assay (Figure S5). Conjugation of the MPP to Cbl, and
the subsequent mitochondrial sequestration, appears to limit
modification and inactivation by the cytoplasmic GST-m. The
comparable toxicity observed in the wild-type and Cbl-resistant
lines supports the notion that targeting and sequestering drugs to
the mt also allows for evasion of a chemical mechanism of drug
resistance.Given thatCbl resistance has beendetected in patients
with leukemia (Pepper, et al., 1999), the ability to evade resistance
with mitochondrial drug delivery may have clinical relevance.
SIGNIFICANCE
We have demonstrated the advantages of targeting the
mitochondria of cancer cells to combat drug resistance445–453, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 449
HL60 K562 OCI-M2 U937
0
25
50
75
100
0
25
50
75
100
Staurosporine-induced apoptosis
Levels of BclxL
-7 -6 -5 -4
0
25
50
75
100
log [MPP-Cbl] (M)
-7 -6 -5 -4 -3 -2
0
25
50
75
100
log [Cbl]  (M)
A C 
D 
Cbl B mt-Cbl 
K562 
OCI-M2 
%
 
T
o
x
i
c
i
t
y
 
%
 
T
o
x
i
c
i
t
y
 
%
 
V
i
a
b
i
l
i
t
y
 
N
o
r
m
.
 
B
c
l
x
L
:
-
a
c
t
i
n
 
R
a
t
i
o
 
Untreated 100uM Cbl 9uM mt-Cbl 
CblR 
WT 
Alive Apoptotic 
Necrotic Dead 
2.8% 2.7% 
92.0% 2.5% 
2.5% 1.8% 
93.4% 1.8% 
2.5% 3.3% 
92.8% 1.4% 
4.5% 25.8% 
66.4% 3.3% 
2.4% 34.6% 
59.4% 3.6% 
8.9% 16.4% 
69.1% 5.6% 
Annexin V-FITC 
S
y
t
o
x
 
R
e
d
 
S
y
t
o
x
 
R
e
d
 
3% 
62% 
21% 
15% 
Annexin V-FITC 
S
y
t
o
x
 
R
e
d
 
3% 15% 
64% 
19% 
l  mt-Cbl]  l l] ( ) 
Annexin V-FITC 
Figure 5. Toxicity of mt-Cbl in Cell Lines Exhibiting Drug Resistance and Apoptotic Resistance
(A) Toxicity of mt-Cbl toward a panel of leukemia cell lines (OCI-M2, K562, HL60, and U937). Mean values plotted, n > 3, error bars are SEM. Inset shows FACS
analysis of HL60 Annexin V-FITC (A-FITC)/SYTOX Red (SR) cell staining after treatment with 6 mM mt-Cbl. Indicated are the percentages of population in each
quadrant (A-FITC-/SR-, alive; FITC+/SR-, apoptotic; A-FITC-/SR+, necrotic; A-FITC+/SR+, dead).
(B) Toxicity of Cbl with leukemia cell lines showed two distinct populations, with HL60 and U937 being sensitive to Cbl and K562 and OCI-M2 being resistant to
Cbl. Inset is the same as (A) but with 34 mM Cbl.
(C) Apoptotic resistance in Cbl-resistant cell lines. Response of leukemia cell lines to staurosporine as measured by FACS analysis of Annexin V-/SYTOX
Red-stained cells (black bars). Graphed are percent viable cells. Staurosporine treatment induced less cell death in the K562 and OCI-M2 cell lines compared to
HL60 and U937. K562 and OCI-M2 cell lines show higher levels of Bcl-XL expression (white bars). Protein levels were determined by western blot analysis of
whole-cell lysates.
(D) Toxicity of mt-Cbl in WT or Cbl-resistant cells (CblR). Cells were treated as in (A). Cbl alone did not show an increase in the apoptotic cell population in CblR;
however, an apoptotic response with mt-Cbl treatment was observed for both WT and CblR cell lines. See also Figure S5.
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Mitochondrial Delivery of Chlorambuciland show that mitochondrial delivery of Cbl results in
a significant gain of potency. Importantly, even though the
MPP directs Cbl to a novel target—the mitochondrial
genome—a therapeutic window was maintained due to
differential membrane potentials between CLL cells and
normal cells. These studies also illustrate thatmitochondrial
compartmentalization of Cbl allows for evasion of drug
resistance both through biochemical mechanisms like
perturbations in the apoptotic pathway, and chemical mech-
anisms like drug inactivation. Therefore, mitochondrial
delivery as a means of ‘‘repurposing’’ FDA-approved drugs
currently used in the clinic appears to be a worthwhile
strategy to pursue in the development of new anticancer
agents.EXPERIMENTAL PROCEDURES
Peptide and Drug Conjugate Synthesis and Characterization
Solid-phase synthesis was performed on Rink amideMBHA resin (0.7 mmol/g,
100–200 mesh) (NovaBiochem) using a Prelude Protein Technologies peptide
synthesizer as described previously (Horton and Kelley, 2009). Peptides were450 Chemistry & Biology 18, 445–453, April 22, 2011 ª2011 Elseviersynthesized on a 25 or 50 mmol scale. Thiazole orange was synthesized as
described previously (Carreon, et al., 2007) and coupled to peptides using
HBTU (4 eq; Protein Technologies, Tucson, Arizona, HBTU = O-(benzotria-
zol-l-yl)-N,N,N’,N’-tetramethyl-uronium hexafluoro-phosphate), and DIPEA
(8 eq; Sigma-Aldrich, St. Louis, DIPEA = N,N-diisopropylethylamine) in N,N-
dimethyl formamide (DMF) overnight. Cbl (Sigma-Aldrich) was coupled to
peptides using HBTU (4 eq) and DIPEA (4 eq) in DMF. The N terminus of
unlabeled peptides was capped using acetic anhydride, pyridine, and
dichloromethane (DCM) (1:5:10; Sigma-Aldrich). Peptides were deprotected
and cleaved from the resin using trifluoroacetic acid (TFA):triisopropylsila-
ne:H2O (95:2.5:2.5) and precipitated in cold ether. All peptides were purified
to >95% purity by RP-HPLC on a C18 column with a H2O/MeCN gradient in
0.1% TFA, and identity was confirmed by electrospray ionization mass spec-
troscopy. Peptides containing Cbl were immediately flash frozen in liquid
nitrogen post-purification and lyophilized to dryness. Thiazole orange-labeled
peptides were quantified at 500 nm using an extinction coefficient of 63,000
M1 cm1 (Horton and Kelley, 2009). Cbl-conjugated peptides were quantified
at 258 nm using the Cbl extinction coefficient of 15,200 M1 cm1. Unlabeled
peptides were quantified using a BCA assay (Pierce, Rockford, Illinois).
Cell Culture
HeLa cells were cultured in MEM alpha (Invitrogen, Carlsbad, California) sup-
plemented with 10% (v/v) FBS at 37C with 5%CO2. U937 cells were cultured
in RPMI 1640 plus 10% FBS, and Iscove’s modified Dulbecco’s media plusLtd All rights reserved
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Daudi. A2780 wild-type and Cbl-resistant lines were cultured in RPMI 1640
plus 10% FBS in a humidified atmosphere at 37C with 5% CO2. The Cbl-
resistant line was treated with 100 mM Cbl once a week for 1 hr to maintain
resistance.
Confocal Microscopy—Live Cells
Cells were seeded in 8-well m-slides (iBidi, Germany) at a density of 25,000
cells per well 1 day prior to experiments. Peptide incubations (5 mM) were per-
formed for the indicated times in OPTI-MEM (Invitrogen). Where stated, Mito-
Tracker 633 (Invitrogen) was added for the last 20 min of the incubation. Cells
were thenwashed twice and imaged using an inverted Zeiss LSM510 confocal
microscope.
Confocal Microscopy—Fixed Cells
HeLa cells were plated as above and treated with 5 mM peptide in MEM alpha
without phenol red (Invitrogen) for 5 min at 37C with 5% CO2. Peptide solu-
tions were then removed and replaced with fresh media for 25 min at 37C
with 5% CO2. Cells were washed twice with PBS and incubated with acetone
for 10 min at 20C. Cells were again washed twice with PBS, incubated with
0.1% Triton X-100 for 5 min at 4C, washed with PBS, and imaged as above.
Where stated, cells were incubated with 10 U DNase in 13 DNase buffer for
2 hr at 37C prior to imaging.
Immunogold/TEM Analysis of Peptide Localization
mt were isolated from fresh mouse liver as previously described (Frezza, et al.,
2007). Functionality was confirmed using respirometry. The isolated organ-
elles were used only when the levels of oxygen consumption in state III respi-
ration (presence of ADP) were >4-fold greater than in state II respiration,
indicating well-coupled mt. Mitochondrial protein concentration was deter-
mined by BCA assay (Sigma-Aldrich). mt were diluted to 0.5 mg/ml in PBS
and incubated for 20 min at 25C with biotin-FxrFxrFxr. Cold PBS was added,
and mt were pelleted by centrifugation. The pellet was fixed in 1% glutaralde-
hyde in PBS for 90 min at room temperature, washed with PBS, and then fixed
with 1% osmium tetroxide for 2 hr at 4C. The pellets were dehydrated using
graded ethanol, followed by stepwise infiltration with propylene oxide and
Epon-Araldite resin. The pellets were cured in resin for 48 hr at 60C . The
blocks were sectioned to 60 nm, and the sections adhered to nickel grids
for 30min at 60C. The grids were floated on saturated aqueous sodiummeta-
periodate for 1 hr at room temperature, washed, then blocked with 1% BSA,
and labeled with Anti-biotin (Jackson Immunolabs), followed by Protein
A-gold (Aurion; 10 nm). The grids were rinsed with water and stained with
2% uranyl acetate for 5 min. To quantitate gold labeling, 200 gold particles
(for more densely labeled samples) or 400 mt (for less densely labeled
samples) were counted for each counting event. A minimum of three counting
events was performed per sample. Counting was performed over different
sections.
Analysis of Mitochondrial Superoxide Levels
HeLa cells were plated at 50,000 per well of a 24-well plate 24 hr prior to exper-
iment and treated with Cbl or mt-Cbl in OPTI-MEM (Invitrogen) for 1 hr. Media
were removed, and cells were incubated with MitoSOX (Invitrogen) according
to manufacturer’s instructions. Cells were washed with PBS, trypsinized, and
analyzed via flow cytometry with FACSCanto (BD, Franklin Lakes, New
Jersey).
Mitochondrial Membrane Potential
HeLa cells were seeded at 50,000 cells per well 24 hr prior to experiment.
Samples from patients with CLL, PBSCs, and healthy donor B cells were
seeded at 200,000 cells per well in triplicate in a 24-well plate in Iscove’s
media. Cells were then incubated with 2 mM of 5,50,6,60-tetrachloro-1,10,3,30-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1; Invitrogen) for 20 min at
37C. Each sample was then washed twice with 1 ml PBS and resuspended
in 300 ml PBS prior to being read on a BD FACSCanto. Samples were excited
at 488 nm, and emission was collected at 526 nm (green) and 595 nm (red). To
obtain the mitochondrial membrane potential (red/green), emission from the
red channel was divided by emission from the green channel. For membrane
depolarization studies, HeLa cells were treated with Cbl or mt-Cbl for 1 hr inChemistry & Biology 18,OPTI-MEM (Invitrogen) prior to incubation with JC-1. Cells were washed
with PBS, trypsinized, and analyzed as above.
Analysis of Toxicity
HeLa cells were seeded in 96-well flat-bottom tissue culture plates (Starstedt,
Germany) at a density of 12,000 cells per well. Leukemic cell lines (K562,
OCI-M2, U937, HL60, OCI-AML2, OCI-LY17, Daudi) were seeded in 96-well
flat-bottom plates (Greiner Bio-One, Germany) at a density of 50,000 cells
per well. A2780 wild-type and A2780 Cbl-resistant cells were plated in
96-well flat-bottom tissue culture plates (Starstedt) at 25,000 cells per well.
The culture media were removed, and cells were washed. Peptide incubations
were conducted in cell-appropriate media; HeLa cell incubations were con-
ducted in OPTI-MEM media. Cellular viability was analyzed after an overnight
incubation at 37C with 5% CO2 using the CCK-8 viability dye (Dojindo, Rock-
ville, Maryland) at an absorbance of 450 nm. Statistical analysis was done
using GraphPad Prism Software (GraphPad, La Jolla, California).
Colorimetric Alkylation Assay
Alkylation was tested using 4-(4-Nitrobenzyl)pyridine (4-NBP) (Thomas, et al.,
1992). Briefly, compound (200–450 mM) was incubated with 4-NBP (0.7% w/
vol) in a buffer containing 85 mM triethanolamine (pH 7.2) and 43% acetone.
Reactions were incubated at 37C for 30–120 min. Reactions were terminated
by freezing in a dry ice/ethanol bath. To develop samples, 100 ml ethyl acetate
and 25 ml 5N NaOH were added followed by vortexing. Absorbance of organic
ethyl acetate was read at 540 nm.
Crosslinking of Isolated DNA
Crosslinking of isolated pBR322 DNA was determined from a modification of
a published method (Sunters, et al., 1992). Briefly, pBR322 DNA was incu-
bated with compounds at concentrations and times indicated in 25 mM
triethanolamine (pH 7.2) and 1 mM EDTA. Reactions were terminated by the
addition of 50 mM EDTA and 150 mg/ml excess short oligonucleotide DNA.
Samples were denatured at 95C in denaturation buffer (30% DMSO, 1 mM
EDTA, bromophenol blue, xylene cyanol, and 0.4% SDS) for 3 min and flash
frozen in a dry ice/ethanol bath. Electrophoresis was carried out in 0.8%
agarose in TAE buffer and stained post-run with ethidium bromide.
Quantitative Real-Time PCR
Six hundred thousand HL60 cells were incubated in Iscove’s media (Invitro-
gen) with Cbl, mt-Cbl, or MPP at the LC25 dose (17, 3, and 3 mM, respectively)
for either 2 or 24 hr as indicated. For Lig3, cells were incubated at an LC50 dose
(34, 6, and 6 mM, respectively) for 1 hr. RNA was then isolated using the
RNeasy Mini-Kit (QIAGEN, Hilden, Germany) according to the manufacturer’s
instructions. RNA was quantified on a NanoDrop, and 1 mg was converted to
cDNA using the RT2 First Strand Kit (SA Biosciences, Frederick, Maryland).
qPCR was then performed using the Human DNA Damage Signaling Pathway
PCR Array (PAHS-029; SA Biosciences) or with selected primers purchased
from SA Biosciences according to manufacturer’s instructions. Data analysis
was performed using the web-based software provided by SA Biosciences.
Lig3, p21, and GAPDH primers were designed independently: LIG3, forward
GAAATGAAGCGAGTCACAAAAGC and reverse GTACCCTTCACATCCTT
CAGC; p21, forward CCTCATCCCGTGTTCTCCTTT and reverse GTACCA
CCCAGCGGACAAGT; and GAPDH, forward CAACGGATTTGGTCGTATTGG
and reverse GCAACAATATCCACTTTACCAGAGTTAA. All other steps were
performed in an analogous manner to the method described above. Genes
showing R4-fold change in expression levels compared to control cells
were considered hits, as recommended by the SA Biosciences’ manufacturer.
All hits were confirmed with three biological replicates using primers
purchased from SA Biosciences.
Determination of DNA Lesion Frequency by Quantitative PCR
A total of 5 3 106 HL60 cells were treated with Cbl (150 mM) or mt-Cbl (3 mM)
for 2 hr. DNA was isolated from frozen cell pellets with the QIAGEN Genomic
Tip and Genomic DNA Buffer Set Kit (QIAGEN) and quantified using the
PicoGreen dye (Invitrogen). Quantitative amplification of the 8.9 kb mitochon-
drial segment and the 17.7 kb b-globin target sequence was performed
using the GeneAmp XL PCR kit (Perkin-Elmer) as described previously
(Santos, et al., 2006). Lesion frequency at a given dose, D, was calculated445–453, April 22, 2011 ª2011 Elsevier Ltd All rights reserved 451
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of amplification in nondamaged controls.
mt-Cbl Labeling of mtDNA
Biotin-labeled mt-Cbl peptide (Biotin-mt-Cbl) was synthesized as previously
described using Fmoc-Lys(Biotin)-Rink Amide resin (AnaSpec, Inc., Fremont,
California). HL-60 cells (25 million cells) were incubated with the compound (0,
1.5 mM) for 30 min, after which the cells were collected. The cells were then
washed with ice-cold PBS, and their mt were isolated using Mitochondrial
Isolation Kit for Mammalian Cells (Thermo Scientific, Rockford, Illinois). The
mtDNA was then extracted from the mitochondrial pellets using AllPrep
DNA/RNAMini Kit (QIAGEN). DNA concentration wasmeasured using a Nano-
Drop 1000 Spectrophotometer (Thermo Scientific) and then normalized
(10 ng/ml). After this, a nitrocellulose membrane was spotted with untreated
and treated DNA and UV crosslinked using UV Stratalinker 1800 (Stratagene,
La Jolla, California) The membrane was blocked with 5%BSA-TBST for 1 hr at
room temperature and then probed with streptavidin-HRP (Sigma-Aldrich) in
5% BSA-TBST (1:5000) at 4C overnight. Then the membrane was washed
and visualized with chemiluminescence detection (GE Amersham, Baie
D’Urfe).
Annexin-V Apoptosis Assay
Leukemic cell lines (K562, OCI-M2, U937, HL60) were seeded at 200,000 cells
per well of a 24-well plate (Greiner Bio-One). A2780wild-type andCbl-resistant
cells were plated in 24-well plate at a density of 75,000 cells per well (BD).
Healthy donor mononuclear cells were obtained by Ficoll separation from
peripheral blood. Samples from patients with CLL, PBSCs, and healthy donor
mononuclear cells were plated at 200,000 per well (Greiner Bio-One). Cells
were incubated in triplicate with peptides at concentrations indicated in cell-
appropriate media. Following overnight incubation at 37C with 5% CO2, cells
were stained with Annexin V-FITC (BD PharMingen, Franklin Lakes, New
Jersey) and SYTOX Red (Invitrogen) according to manufacturer’s instructions.
Flow cytometry was performed using a FACSCanto (BD). Apoptotic induction
by staurosporine was accomplished by addition of 3 mM staurosporine
(Sigma-Aldrich) with an overnight incubation.
Colony-Forming Assay
To assess clonogenic growth, primary AML cells (43 105/ml) were treatedwith
mt-Cbl in Iscove’s media for 2 hr. After treatment, cells were washed, and 105
cells/ml were plated by equal volume in duplicate in MethoCult GF H4434
medium (StemCell Technologies, Vancouver, British Columbia, Canada) con-
taining 1% methylcellulose in IMDM, 30% FCS, 1% bovine serum albumin,
3 U/ml of recombinant human erythropoietin, 104 M of 2-mercaptoethanol,
2 mM of L-glutamine, 50 ng/ml of recombinant human stem cell factor,
10 ng/ml of GM-CSF, and 10 ng/ml of rh IL-3. Seven days after plating, the
number of colonies containing ten or more cells was counted as previously
described (Buick, et al., 1977).
Western Blots
Leukemia cells were cultured as above and were washed twice with PBS prior
to lysis in either Ripa Buffer or 10 mM Tris, 200 mMNaCl, 1 mM EDTA (pH 7.4),
1 mM PMSF, 0.5% NP-40, 1% Triton X-100, 13 Protease Inhibitor Cocktail
(BioShop, Burlington, Ontario, Canada) at 4C, 30 min. Cells were then centri-
fuged at 1200 rcf, 4C, 5 min, and protein levels were quantified using bicin-
choninic acid (BCA) assay (Pierce). Fifteen to 50 mg of total protein was diluted
in 83 sample buffer and heated to 42C for 5 min prior to loading on 10% or
15% gel. Gels were run at 100 V for 1 hr, and then proteins were transferred
onto nitrocellulose or PVDF membranes at 100 V for 1 hr. Membranes were
blocked with 5% skim milk or 5% BSA for 1 hr and then probed with primary
antibody according to manufacturer’s instructions (1:500 BclXL antibody [Ab-
cam, Cambridge, Massachusetts], 1:2000 b-actin antibody [Abcam], 1:1000
phospho JNK [Abcam], 1:1000 phospho p38 [Abcam], 1:1000 GADD45G
[Santa Cruz Biotechnology, Santa Cruz, California], 1:1000 PPP1R15A [Santa
Cruz Biotechnology], 1:1000 DNA Ligase III [Santa Cruz Biotechnology],
1:1000 p21 [Santa Cruz Biotechnology], and 1:1000 DDIT3 [Cell Signaling
Technology, Beverly, Massachusetts]). Membranes were then washed and
incubated with 1:5000 donkey anti-mouse or goat anti-rabbit IgG-HRP452 Chemistry & Biology 18, 445–453, April 22, 2011 ª2011 Elseviersecondary antibody for 1 hr prior to ECL chemiluminescence detection
(GE Amersham).
Collection of Patient Samples
Peripheral blood cells from normal individuals and patients with CLL were
collected following written informed consent according to a research ethics
board (REB) approved protocol. Mononuclear cells were isolated by Ficoll-Hy-
paque centrifugation. The cells were either used fresh or stored in a viable state
at 150C in 10% DMSO, 40% FBS, and alpha medium. PBSCs were excess
filgrastim-mobilized cells obtained from stem cell transplant donors obtained
according to an REB approved protocol.
Hemolysis Assay
Red blood cells obtained during Ficoll separation of healthy donor peripheral
blood were used for this assay. Cells were washed with PBS until the superna-
tant was clear. Peptide solutions were made in Iscove’s media, and a 1:2 dilu-
tion was made across a 96-well plate. To each well, 2 ml of red blood cells was
added, mixed, and then incubated for 1 hr at 37C with 5% CO2. For 100%
lysis, 0.1% Triton X-100 was added to three wells, and for 0% lysis, cells
from three wells without peptide were used. Plates were spun at 1000 3 g
for 10 min, and 50 ml of supernatant was then transferred to a new plate, mixed
with 50 ml of PBS, and read at 415 nm to assess for hemolysis.
Peptide Uptake Evaluation
Samples from patients with CLL, PBSCs, and healthy donor B cells were
seeded at 200,000 cells per well in triplicate in a 24-well plate in Iscove’s
media. To determine FCCP effects, cells were pretreated for 15 min with
10 mMFCCP. Cells were then incubated with 2 or 5 mM thiazole orange-labeled
peptide for 15 min, washed with PBS, and analyzed on FACSCanto (BD) to
determine relative intracellular peptide concentrations.
SUPPLEMENTAL INFORMATION
Supplemental Information includes five figures and two tables and can be
found with this article online at doi:10.1016/j.chembiol.2011.02.010.
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